- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare ITI Pharma and Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.91 |
NAV | ₹16.74 | ₹38.67 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹230.79 Cr | ₹5320.29 Cr |
Exit Load | Exit load of 1% if redeemed within 12 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.35
1.91
NAV
₹16.74
₹38.67
Fund Started
18 Oct 2021
25 Jun 2018
Fund Size
₹230.79 Cr
₹5320.29 Cr
Exit Load
Exit load of 1% if redeemed within 12 months.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 31.30% | 37.66% |
3 Year | 18.18% | 23.26% |
5 Year | - | 29.75% |
1 Year
31.30%
37.66%
3 Year
18.18%
23.26%
5 Year
-
29.75%
Holding Analysis
Equity | 97.91% | 98.07% |
Cash | 1.09% | 1.93% |
Equity
97.91%
98.07%
Cash
1.09%
1.93%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 15.23% |
Lupin Ltd. | 6.53% |
Divi's Laboratories Ltd. | 5.02% |
Aurobindo Pharma Ltd. | 4.94% |
Suven Pharmaceuticals Ltd. | 4.84% |
Apollo Hospitals Enterprise Ltd. | 4.80% |
Max Healthcare Institute Ltd. | 3.84% |
Torrent Pharmaceuticals Ltd. | 3.53% |
Laurus Labs Ltd. | 3.21% |
Dr. Reddy's Laboratories Ltd. | 2.93% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Fund Manager
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Dhimant Shah
Dharmesh Kakkad
Start Date
01 Dec 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
18 Oct 2021
25 Jun 2018
